Bangkok, Thailand – September 3, 2024: The Health Systems Research Institute (HSRI) and Roche Thailand have signed a Memorandum of Understanding (MOU) to foster collaboration in the health system development and research in Thailand. The signing ceremony was attended by Dr. Supakit Sirilak, Director of HSRI, along with the institute’s board members, and Matthew Coates, General Manager of Roche Thailand. This partnership aims to pioneer initiatives and encourage all sectors to invest comprehensively in the public health system, with the ultimate goal of maximizing benefits for the Thai people.
This signing marks a significant step as both organizations collaborate to support and enhance the sustainability and effectiveness of Thailand's public health system. The partnership between HSRI and Roche Thailand will focus on research and various initiatives aimed at improving the quality of life for the Thai people and providing a foundation for the development of robust health policies.
Over the past decade, Roche Thailand has treated more than 3 million patients nationwide with innovative medicines that have undergone rigorous trials and received approval as innovative therapies. Roche has also collaborated with various sectors to support and conduct health system research, aiming to foster benefits that strengthen and promote the sustainability of Thailand's healthcare system in, quality of life, societal and economical dimensions.
In 2024, Roche Thailand collaborated with Yonder, a UK-based research company, to survey the opinions of the Thai public regarding the country's healthcare system. The survey revealed that over 47% of respondents wanted the government to increase its budget investment in public health. Additionally, medical professionals emphasized that investing in health system support is an urgent priority in the current national context, highlighting the need for Thailand to increase healthcare investment significantly. Whereby, the signing between HSRI and Roche will serve as a key driver in making these public needs a reality.
Dr. Supakit Sirilak, Director of the Health Systems Research Institute (HSRI), stated at the signing ceremony: "HSRI focuses on system-based research that drives meaningful changes in Thailand's health system, aligned with our organization's objectives and philosophy. Notable examples of our work include the 30-Baht Universal Healthcare Scheme, Universal Health Coverage, and the development of benefit packages, as well as biomedical research covering pharmaceuticals and medical devices, among others. However, HSRI cannot achieve these goals on its own. Today's collaboration with Roche Thailand is a critical catalyst in supporting the development of a sustainable and high-quality healthcare system in Thailand."
Matthew Coates, General Manager of Roche Thailand, added, "Roche is confident that this collaboration with HSRI to to enhance the development of Thailand’s health system will help improve equitable access to innovative medicines for all patients. It will also drive policy changes and increase investment in the public health system, particularly for cancer, which remains a leading cause of death in Thailand. Roche remains committed to pioneering science into meaningful breakthroughs for patients to enhance the quality of life for people today and in the future."
Today's signing of the Memorandum of Understanding marks just the first step in a collaboration aimed at advancing health research and policy in Thailand. The goal is to elevate healthcare standards and strengthen the country's public health system, which will have a direct impact on the quality of life for its citizens and contribute to the long-term sustainability of the health system.
M-TH-00004043
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid